New Talk: High Throughput Viral Titering of AAV Throughout the Production Continuum
Kelly Geosits, Research & Development Associate Scientist, Center for Breakthrough Medicines
Process development for viral vector manufacturing relies on accurate titers to inform critical decisions. Digital PCR is the established titer method to support AAV manufacturing, but droplet-based methods have historically been challenged by matrix effects and long time to data.
In this on-demand webinar, learn how the Center for Breakthrough Medicines (CBM) has applied nanoplate-based QIAcuity digital PCR technology to achieve accurate titers from multiplexed assays with challenging samples.
What you will learn:
- – How new advances in digital PCR provide more data, across more sample types, faster, and with higher throughput
- – Critical factors to consider when choosing automated platforms for AAV viral titer determination
- – Strategies to efficiently quantify more targets in the same sample
- – Pushing past common droplet busting matrices to expand testing throughout the AAV process continuum
In need of immediate assistance with analytical development and testing? Contact us here or simply call to speak with a CBM expert: 866-274-4009.